Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lumexa Imaging is a nationwide provider of diagnostic imaging services and outpatient medical imaging, and its filings offer detailed insight into its capital structure, governance and material agreements.
Investors can review Lumexa’s registration statement and related documents associated with its initial public offering on the Nasdaq Global Select Market, as well as subsequent Current Reports on Form 8-K. For example, recent 8-K filings describe the completion of the IPO, the execution of an underwriting agreement and stockholders agreement, adoption of an Amended and Restated Certificate of Incorporation and Bylaws, and entry into indemnification agreements with directors and executive officers.
Another 8-K filing outlines an amended credit agreement that provides Lumexa Imaging subsidiaries with a secured term loan facility and a secured revolving credit facility. The filing details interest rate terms, maturities, restrictive covenants and a leverage-related financial covenant, along with guarantees and security interests from substantially all wholly owned subsidiaries, subject to specified exceptions. These disclosures help readers understand Lumexa’s borrowing arrangements and related obligations.
On this page, users can track Lumexa Imaging’s Forms 10-K and 10-Q when filed, along with additional 8-Ks, proxy statements and other submissions. Stock Titan enhances these documents with AI-powered summaries that explain key sections, highlight important covenants and capital structure details, and make lengthy filings more accessible. The platform also surfaces insider transaction reports on Form 4, enabling users to monitor equity transactions by Lumexa’s directors and executive officers in one place.
Lumexa Imaging Holdings, Inc. is asking stockholders to elect three Class I directors—Lee Cooper, Brian Regan and CEO Caitlin Zulla—to terms running until the 2029 annual meeting, and to ratify PwC as independent auditor for the year ending December 31, 2026.
The 2026 annual meeting will be held virtually on June 10, 2026 at 8:30 a.m. Eastern Time via webcast at www.proxydocs.com/LMRI, with advance online registration required by June 5, 2026. Holders of the company’s 96,110,039 outstanding common shares as of April 13, 2026 may vote.
The proxy also details board structure, committee memberships and independence, director retainers and annual equity awards, and 2025 executive pay. CEO Caitlin Zulla received a $750,000 salary, a $3.5 million signing bonus, equity awards tied to stock-price hurdles and a 2025 bonus based on Adjusted EBITDA and strategic goals.
Lumexa Imaging Holdings, Inc. reported that on April 8, 2026 it held a meeting and site visit where it reiterated its previously disclosed full year 2026 guidance. The company stated this information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act unless specifically designated or incorporated by reference.
Lumexa Imaging Holdings, Inc. reports full-year 2025 results as a newly public, national diagnostic imaging platform. The company operated 188 outpatient centers across 13 states as of December 31, 2025, supported by roughly 102,000 referring physicians from more than 32,000 practices.
Consolidated revenue reached $1.023 billion for 2025, up 7.8% from 2024, while system-wide revenue, which includes unconsolidated joint ventures, also grew 8.2%. Lumexa recorded a 2025 net loss of $47.1 million but generated Adjusted EBITDA of $230.2 million, a 22.5% margin, reflecting scale and operating leverage.
During 2025 the company completed an IPO of 25,000,000 common shares, raising approximately $427 million in net proceeds. Advanced imaging, particularly MRI and CT, was a key driver, accounting for 52% of consolidated revenue and 63% of system-wide revenue. Management highlights strong patient satisfaction, expansive health system joint ventures, and growing use of third-party AI and teleradiology (Connexia) as core competitive strengths.
Lumexa Imaging Holdings, Inc. reported preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025 and reiterated its full-year 2026 guidance. Full-year 2025 total revenues rose to $1,023,081 thousand from $948,869 thousand, while net loss narrowed to $47,104 thousand from $94,099 thousand. Adjusted EBITDA increased to $230,154 thousand from $200,839 thousand, reflecting stronger operating performance. Basic and diluted loss per share improved to $0.66 from $1.35. Outpatient volumes grew, with consolidated total procedures up 4.6% for 2025 and consolidated advanced procedures up 7.8%. The company strengthened its balance sheet: cash and cash equivalents increased to $58,828 thousand from $26,131 thousand, and long-term debt (less current maturities) declined to $819,029 thousand from $1,185,080 thousand, supported by initial public offering proceeds of $434,750 thousand.
Lumexa Imaging Holdings, Inc. released preliminary, unaudited fourth quarter and full year 2025 results and issued 2026 guidance. For 2025, GAAP net loss was $43,768 thousand, improving from $94,099 thousand in 2024, while Adjusted EBITDA rose to $229,029 thousand from $200,839 thousand. Fourth quarter 2025 Adjusted EBITDA was $62,625 thousand, up from $53,742 thousand a year earlier, with management citing expected Adjusted EBITDA growth of at least 14%. System-wide total procedures reached 3,972,228 in 2025, with advanced procedures growing and PET volumes up 17.0% on a consolidated basis and 13.5% system-wide. The company highlights expansion of de novo centers, one acquisition, new joint venture partnerships, and early adoption of AI-powered breast arterial calcification assessments as drivers of growth.
Lumexa Imaging Holdings, Inc. reported that its Principal Accounting Officer, Walker James Edward Jr., acquired 12,414 shares of common stock in the form of restricted stock units. The grant carried a price of $0.0000 per share, indicating it was an equity award rather than an open-market purchase.
Each RSU represents the contingent right to receive one share of Lumexa common stock. The RSUs vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, conditioned on Mr. Walker’s continued service with the company. Following this award, his directly owned common stock and RSUs total 17,346 shares.
Welsh, Carson, Anderson & Stowe entities report majority ownership of Lumexa Imaging Holdings, Inc. The reporting group, through Lumexa Imaging Holdings, LLC, beneficially owns 70,217,616 shares of Lumexa common stock, representing 74.3% of the company’s outstanding shares.
These percentages are based on 94,565,652 shares of common stock outstanding after Lumexa’s initial public offering, as stated in the company’s final prospectus. The ownership is shared among Welsh, Carson, Anderson & Stowe XII, L.P., WCAS XII Associates LLC, and WCAS Management Corporation, reflecting their control and investment advisory roles.
After a 180-day lock-up period following the December 12, 2025 IPO closing, Lumexa Imaging Holdings, LLC may distribute its shares to equity holders on a pro rata basis. Up to 28,595,386 shares could be received by various Welsh, Carson, Anderson & Stowe affiliates in a full distribution, while remaining shares would go to unaffiliated holders, reducing the group’s shared beneficial ownership.
Lumexa Imaging Holdings, Inc. reported that its Chief Financial Officer, Martin James Anthony, received two grants of common-stock-based compensation on December 12, 2025. Each grant covers 27,027 restricted stock units (RSUs) at a price of $0 per share, for a total of 54,054 RSUs now beneficially owned directly.
One RSU grant vests in three roughly equal annual installments on each of the first three anniversaries of the grant date, as long as he remains with the company. The second grant vests in three equal parts if the stock reaches volume-weighted average price targets of $27.00, $36.00 and $45.00 over any 60‑trading‑day period within up to four years, also subject to continued service.
Lumexa Imaging Holdings, Inc. reported initial equity holdings for Chief Financial Officer Martin James Anthony. He beneficially holds two stock option awards, each covering 388,888 shares of common stock at an exercise price of $18.50 per share. One option vests in five substantially equal annual installments starting from January 1, 2025, conditioned on his continued service. The second option vests in three installments tied to stock price targets of $27.00, $36.00, and $45.00 per share, measured over any 60‑trading‑day volume weighted average price after a 180‑day lock‑up period, also requiring continued service. The filing notes it was submitted late due to delays obtaining EDGAR codes.